It is a public–private partnership between Finnish universities, the National Institute for Health and Welfare, the Finnish Red Cross Blood Service, the biobanks, which are mostly owned by independent hospital districts, hospitals, and pharmaceutical companies including Abbvie, AstraZeneca, Biogen, Celgene, Genentech, GSK, Janssen, Maze Therapeutics, Merck, Novartis, Pfizer, and Sanofi.

500,000 blood samples are to be collected over six years by a nation-wide network of Finnish biobanks and they will be matched with national health records, 98% of which are available in an electronic format.

It claims that it will manage the anonymous health registry and the genomic data without compromising the privacy and integrity of participants.

[7] The first summary of results was released to the public on January 14, 2020 [8] and will be updated every 6 months, at a one year delay with the internal findings.

The low level of variants in the population structure means the chances that any disease association findings will have statistical significance are greater.